This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): R1583, RG1583, BIM 51077, ITM-077, RO5073031
Description: Taspoglutide is a long-acting glucagon-like-peptide-1 (GLP-1) analogue, given by injection. It uses aminoisobutyric acid (Aib) substitutions and zinc to prolong its half-life. It is anticipated that the final formulation will utilize a 29 gauge needle, and will not require reconstitution.
GLP-1 is an incretin hormone secreted in the small intestine and colon in response to food intake. It enhances insulin secretion when glucose levels are high, suppresses inappropriate glucagons secretion (glucagon has the opposite effect of insulin), slows gastric emptying (slowing entry of ingested nutrients into the bloodstream, hence limiting post-prandial glucose), and via actions on the brain is thought to promote satiety.
Ipsen and Roche
In October 2003, Roche and Ipsen announced that the two companies entered into a second agreement, following the one concluded December 2002, for Ipsens taspoglutide. In addition to taspoglutide itself , Roche has been granted rights to all future compounds to be discovered or licensed by Ipsen in this class of drugs.
According to the terms of the first agreement entered in December 2002, Roche already has worldwide rights, excluding Europe, to market Ipsens homocamptothecine class of compounds.
In July 2006, Roche announced its decision to exercise its option to exclusively licence, develop and market Ipsens taspoglutide. Roche has been granted worldwide rights, except in Japan where these rights are shared with Teijin (Ipsens Japanese partner), and in France where Ipsen may elect to retain co-marketing rights.
The exercise of this option by Roche has triggered a payment to Ipsen of 56 million. Roche will also make a payment of ca.3 million after the...See full deal structure in Biomedtracker
Partners: Chugai Pharmaceutical Co., Ltd. Teijin Pharma Limited
Additional information available to subscribers only: